Immunophenotyping data indicate that the combination of CD38 and CD138, another known marker of fully differentiated plasma cells, is a validated strategy to identify CD45+ myeloma and separate CD20+ myeloma from B-cell lymphoma. The gene discussed is PTPRC; the disease is plasma cell myeloma.